Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Healthcare
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

GlobeNewswire July 27, 2023

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

GlobeNewswire July 10, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 7, 2023

FULC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC

Newsfile June 27, 2023

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and Last Few Hours to Actively Participate

Newsfile June 27, 2023

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 27, 2023

FULC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2023 in the Class Action Filed on Behalf of Fulcrum Therapeutics, Inc. Shareholders

PR Newswire June 27, 2023

FULC DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC

Newsfile June 26, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)

Business Wire June 26, 2023

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire June 26, 2023

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 26, 2023

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fulcrum Investors of a Lead Plaintiff Deadline of June 27, 2023

PR Newswire June 26, 2023

FULC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC

PR Newswire June 25, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fulcrum Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FULC

PR Newswire June 23, 2023

FULCRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire June 23, 2023

FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire June 23, 2023

FINAL DEADLINE MONDAY: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire June 23, 2023

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 23, 2023

FULC SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulcrum Shareholders of a Lead Plaintiff Deadline of June 27, 2023

PR Newswire June 23, 2023

Upcoming Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and to Actively Participate

Business Wire June 22, 2023